Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO>Duoning Biotech Applies for HK Listing; WUXI BIO Largest Client
Recommend 13 Positive 14 Negative 7 |
||||
|
||||
|
Shanghai Duoning Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International serving as joint sponsors. The company mainly serves pharmaceutical companies, contract research organizations (CRO), contract development and manufacturing organizations (CDMO), and research institutions, providing bioprocess solutions and laboratory products and services, according to the information. Based on 2024 revenue, the top ten biopharmaceutical companies in China are clients of the company, with WUXI BIO (02269.HK) being one of its largest clients and suppliers. WuXi Biologics, CSPC PHARMA (01093.HK), AKESO (09926.HK), and KEYMED BIO-B (02162.HK) are also its shareholders. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
